GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (NAS:THMO) » Definitions » Enterprise Value

ThermoGenesis Holdings (ThermoGenesis Holdings) Enterprise Value : $13.96 Mil (As of Apr. 27, 2024)


View and export this data going back to 1987. Start your Free Trial

What is ThermoGenesis Holdings Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, ThermoGenesis Holdings's Enterprise Value is $13.96 Mil. ThermoGenesis Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.89 Mil. Therefore, ThermoGenesis Holdings's EV-to-EBIT ratio for today is -1.57.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, ThermoGenesis Holdings's Enterprise Value is $13.96 Mil. ThermoGenesis Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.74 Mil. Therefore, ThermoGenesis Holdings's EV-to-EBITDA ratio for today is -1.80.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, ThermoGenesis Holdings's Enterprise Value is $13.96 Mil. ThermoGenesis Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $9.45 Mil. Therefore, ThermoGenesis Holdings's EV-to-Revenue ratio for today is 1.48.


ThermoGenesis Holdings Enterprise Value Historical Data

The historical data trend for ThermoGenesis Holdings's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings Enterprise Value Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.58 19.26 14.78 8.53 8.81

ThermoGenesis Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.53 7.44 7.90 7.32 8.81

Competitive Comparison of ThermoGenesis Holdings's Enterprise Value

For the Medical Devices subindustry, ThermoGenesis Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's Enterprise Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's Enterprise Value distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's Enterprise Value falls into.



ThermoGenesis Holdings Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

ThermoGenesis Holdings's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

ThermoGenesis Holdings's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ThermoGenesis Holdings  (NAS:THMO) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

ThermoGenesis Holdings's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=13.964/-8.887
=-1.57

ThermoGenesis Holdings's current Enterprise Value is $13.96 Mil.
ThermoGenesis Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.89 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

ThermoGenesis Holdings's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=13.964/-7.74
=-1.80

ThermoGenesis Holdings's current Enterprise Value is $13.96 Mil.
ThermoGenesis Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.74 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

ThermoGenesis Holdings's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=13.964/9.445
=1.48

ThermoGenesis Holdings's current Enterprise Value is $13.96 Mil.
ThermoGenesis Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ThermoGenesis Holdings Enterprise Value Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings (ThermoGenesis Holdings) Business Description

Traded in Other Exchanges
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.
Executives
Xiaochun Xu director 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Biao Xi director C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
James Xu director 2453 S. ARCHER AVE, SUITE B, CHICAGO IL 60616
Haihong Zhu director 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Debra Donaghy director C/O THERMOGENESIS HOLDINGS, INC., 2711 CITRUS RD., RANCHO CORDOVA CA 95742
Boyalife (hong Kong) Ltd 10 percent owner 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Thomis Joseph director MALEIZENSTRAAT 66, HERENT C9 B-3020
Boyalife Asset Holding Ii, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Boyalife Group, Inc. 10 percent owner 2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Russell M Medford director 7935 FAWNDALE WAY, ATLANTA GA 30350
Mark Westgate director 350 CORPORATE BOULEVARD, ROBBINSVILLE NJ 08691
Jeffery Cauble officer: Principal Accounting Officer 2711 CITRUS CT., RANCHO CORDOVA CA 95742
Vivian H Liu director
Boyalife Investment Inc. 10 percent owner 2453 S. ARCHER AVE., STE. B, CHICAGO IL 60616
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545

ThermoGenesis Holdings (ThermoGenesis Holdings) Headlines